UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism

Alimentary pharmacology & therapeutics, 2012-09, Vol.36 (5), p.449-458

2012

Volltextzugriff (PDF)

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics

Gut, 2000-10, Vol.47 (4), p.487-496

2000

Volltextzugriff (PDF)

Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn’s disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density

Gut, 2004-08, Vol.53 (8), p.1129-1136

2004

Volltextzugriff (PDF)

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease

Gastroenterology (New York, N.Y. 1943), 1999-12, Vol.117 (6), p.1278-1287

1999

Volltextzugriff (PDF)

High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis

Gut, 2001-11, Vol.49 (5), p.671-677

2001

Volltextzugriff (PDF)

Infliximab in the treatment of medically refractory indeterminate colitis

Alimentary pharmacology & therapeutics, 2003-10, Vol.18 (7), p.741-747

2003

Volltextzugriff (PDF)

Long‐term outcomes of thalidomide in refractory Crohn's disease

Alimentary pharmacology & therapeutics, 2015-03, Vol.41 (5), p.429-437

2015

Volltextzugriff (PDF)

Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup

Gastroenterology (New York, N.Y. 1943), 1996-06, Vol.110 (6), p.1810-1819

1996

Volltextzugriff (PDF)

Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU)

Endoscopy, 2008-01, Vol.40 (1), p.30-35

2008

Volltextzugriff (PDF)

Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis

The American journal of gastroenterology, 2000-08, Vol.95 (8), p.2000-2008

2000

Volltextzugriff (PDF)

Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease

Gastroenterology (New York, N.Y. 1943), 2004-02, Vol.126 (2), p.414-424

2004

Volltextzugriff (PDF)

Serum Immune Responses Predict Rapid Disease Progression among Children with Crohn's Disease: Immune Responses Predict Disease Progression

The American journal of gastroenterology, 2006-02, Vol.101 (2), p.360-367

2006

Volltextzugriff (PDF)

Anti–tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report

Gastroenterology (New York, N.Y. 1943), 2001-03, Vol.120 (4), p.995-999

2001

Volltextzugriff (PDF)

Linkage of Crohn’s disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-κB activation

Gut, 2009-01, Vol.58 (1), p.60-67

2009

Volltextzugriff (PDF)

Crohn’s ileitis after liver transplantation from a living related donor with Crohn’s disease

Gut, 2004-09, Vol.53 (9), p.1389-1390

2004

Volltextzugriff (PDF)

An open‐label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6‐mercaptopurine therapy

Inflammatory bowel diseases, 2001-08, Vol.7 (3), p.181-189

2001

Volltextzugriff (PDF)

A pilot study of adalimumab in infliximab‐allergic patients

Inflammatory bowel diseases, 2004-07, Vol.10 (4), p.333-338

2004

Volltextzugriff (PDF)

The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase‐2 inhibitors in patients with inflammatory bowel disease

Inflammatory bowel diseases, 2004-07, Vol.10 (4), p.352-356

2004

Volltextzugriff (PDF)

Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications

Diseases of the colon & rectum, 1999-05, Vol.42 (5), p.601-606

1999

Volltextzugriff (PDF)

Monoclonal antibody therapy in inflammatory bowel disease

Nestlé Nutrition workshop series. Clinical & performance programme, 1999, Vol.2, p.237-52; discussion 253-5

Vasiliauskas, E A

1999

Volltextzugriff (PDF)

Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease

Inflammatory bowel diseases, 2000-02, Vol.6 (1), p.16-20

2000

Volltextzugriff (PDF)

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease

Gastroenterology (New York, N.Y. 1943), 2002-04, Vol.122 (4), p.904-915

2002

Volltextzugriff (PDF)

Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease

Gastroenterology (New York, N.Y. 1943), 2002-09, Vol.123 (3), p.679-688

2002

Volltextzugriff (PDF)

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

Gastroenterology (New York, N.Y. 1943), 2003-08, Vol.125 (2), p.298-303

2003

Volltextzugriff (PDF)

Safety and Efficacy of Adalimumab (D2E7) in Crohn's Disease Patients with an Attenuated Response to Infliximab

The American journal of gastroenterology, 2005-01, Vol.100 (1), p.75-79

2005

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(80)

Publikationsform

Sprache

Englisch
(97)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Life Sciences & Biomedicine
(61)
Humans
(53)
Gastroenterology & Hepatology
(43)
Female
(40)
Male
(40)
Adult
(34)
Biological And Medical Sciences
(28)
Medical Sciences
(26)
Middle Aged
(25)
Adolescent
(17)
Aged
(16)
Gastroenterology. Liver. Pancreas. Abdomen
(15)
Other Diseases. Semiology
(13)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(13)
Treatment Outcome
(12)
Child
(11)
Crohn Disease - Immunology
(11)
Inflammatory Bowel Disease
(11)
Crohn Disease - Drug Therapy
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics

Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn’s disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease

High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis

Infliximab in the treatment of medically refractory indeterminate colitis

Long‐term outcomes of thalidomide in refractory Crohn's disease

Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup

Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU)

Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis

Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease

Serum Immune Responses Predict Rapid Disease Progression among Children with Crohn's Disease: Immune Responses Predict Disease Progression

Anti–tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report

Linkage of Crohn’s disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-κB activation

Crohn’s ileitis after liver transplantation from a living related donor with Crohn’s disease

An open‐label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6‐mercaptopurine therapy

A pilot study of adalimumab in infliximab‐allergic patients

The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase‐2 inhibitors in patients with inflammatory bowel disease

Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications

Monoclonal antibody therapy in inflammatory bowel disease

Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease

Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

Safety and Efficacy of Adalimumab (D2E7) in Crohn's Disease Patients with an Attenuated Response to Infliximab

Suchergebnisse filtern